Wellnex Life Reports H1 FY26 Results: Revenue Up 8%, Achieves Operating Breakeven

Wellnex Life H1 FY26: revenue up, margins up, and Q2 breakeven

Wellnex Life (ASX/AIM: WNX) has reported an encouraging first half to FY26. Revenue rose 8.0% to $12.919 million, gross margin stepped up 9.4 percentage points to 32.1%, and management says the Group finished Q2 FY26 operating at breakeven. The statutory loss narrowed sharply to $1.793 million, down 76.2% year-on-year.

This is an unaudited half-year with an auditor’s review attached. The review draws attention to a material uncertainty over going concern – more on that below – but otherwise the operational story shows a clear push to become leaner and more disciplined.

Key numbers investors should know

Revenue	$12.919 million (+8.0%)
Gross margin	32.1% (up 9.4 percentage points)
Statutory loss after tax	$(1.793) million (down 76.2%)
Basic loss per share	2.56 cents
Operating cash flow	$(3.142) million
Cash at period end	$975,000
Current borrowings	$5.215 million
Non-current borrowings	$4.819 million
Net assets	$10.044 million
Net tangible assets per share	(13.06) cents
Brand sales as % of revenue	72.3%
Pain Away H1 sales	$7.0 million

What drove the turnaround in H1 FY26

Management kicked off a strategic turnaround aimed at a leaner, more efficient operation with tighter capital management. In simple terms: spend smarter, execute better. The immediate payoff shows up in the 32.1% gross margin – that’s up 9.4 percentage points versus the prior period, indicating improved cost control and pricing discipline.

“Operating breakeven” means the business covered its operating costs in Q2 FY26, before financing charges and other below-the-line items. It’s a useful milestone because sustained operating breakeven can convert quickly into cash generation if sales momentum holds.

Pain Away leads the line-up, new launches lined up for H2

Pain Away remains the flagship. It delivered $7.0 million of sales in H1 FY26 with a 7.9% improvement in gross margin. Pharmacy scan data looks healthy: Heat patch volumes rose 30.8% in Pharmacy against just 0.2% across all other heat patches and 1.4% for the wider topical pain category. Market share for patches hit 19.5% for the period, up 3.8 points year-on-year.

Roll-ons grew 6% versus 1.4% for the category, with two SKUs ranked #1 and #3. A third roll-on is planned for launch in H2 FY26. Distribution continues to build: Priceline is launching five new SKUs nationwide, three major pharmacy wholesalers have confirmed four new product launches, and Costco Australia and Costco New Zealand will trial an exclusive heat patch in H2 FY26.

Wakey Wakey/Nighty Night is being trimmed back, with underperforming SKUs consolidated and investment to cease after customer commitments are met. Mr Bright (teeth whitening) is discontinued, with IP to be divested. On the upside, Wagner Liquigesic – a jointly owned brand with Chemist Warehouse – continues to grow following Australia’s first TGA-approved soft gel liquid paracetamol. The range now includes Paracetamol, Paracetamol and Ibuprofen, and Mini Ibuprofen products.

Geography and customer concentration

Sales remain largely Australasian and UK-centric: Australia contributed $11.017 million, the United Kingdom $1.531 million, New Zealand $48,000, and the United Arab Emirates $323,000. Five individual customers collectively accounted for $9.907 million of revenue. Concentration like that isn’t unusual in consumer healthcare but it does mean execution with a small group of key partners really matters.

Cash, debt and funding: what’s behind the headline

Cash closed at $975,000. Operating cash outflow was $(3.142) million, improved on last year but still negative. Financing flows offset this, helped by new borrowings. During the half, Wellnex Life put in place asset-based loan agreements totalling $5.325 million, with $4.950 million drawn at period end. These loans carry 14% interest and a 3% establishment fee, secured over company assets, with a 24-month term.

The company also maintains a revolving trade debtor facility with a $3.8 million limit, drawn to $2.170 million at 31 December 2025, priced at BBSY + 4%. Related party loans stood at $2.969 million; these are unsecured, now carry 10% interest, and most have been extended to 20 April 2026.

Post period end, the company is reviewing options to raise capital, including funding to settle related party loans. That would simplify the balance sheet and reduce near-term refinancing risk, though terms are not disclosed.

Balance sheet shape and NTA

Total assets were $27.826 million, including $19.179 million of intangibles, mainly brands. That heavy intangible base explains the negative net tangible assets per share of (13.06) cents. On the positive side, trade and other payables fell to $7.538 million and inventories dropped to $2.919 million, which helps working capital discipline. Net assets were $10.044 million.

Auditor’s review and going concern: what to watch

The auditor’s review highlights a material uncertainty related to going concern. The company recorded a $(1.793) million loss, net operating cash outflows of $(3.142) million, and net current liabilities of $4.252 million at 31 December 2025. Those are the red flags.

Management counters with: improving gross margins, Q2 FY26 operating breakeven, a targeted cost reduction programme aiming for over $1 million in annualised savings, unsolicited preliminary interest in certain assets, and the ability to raise equity and/or additional debt via existing brokers and financiers. None of that removes the uncertainty today, but it sets out tangible levers to bridge to profitability.

My take: constructive progress, funding still the swing factor

On the operations side, this was a good half. Margin expansion of 9.4 percentage points to 32.1% is meaningful, and Pain Away’s market share and distribution wins suggest the brand is doing the heavy lifting. Achieving operating breakeven in Q2 FY26 is a confidence-builder for H2.

The counterweight is the balance sheet. Cash is tight at $975,000, current borrowings are significant, and related party loans at 10% add cost until they are refinanced or repaid. The new 14% asset-based facility gives runway but it is not cheap, so execution needs to stay sharp to avoid margin give-back.

Net-net, I see a business that is tightening up and finding its commercial stride, but it still needs a clean funding solution. Any capital raise or asset monetisation – even a modest one – could relieve near-term pressure and help convert the operational momentum into sustained profitability.

Outlook for H2 FY26: what success looks like

• Hold the 32.1% gross margin or better as new launches land and promotions ebb and flow.
• Convert distribution gains at Priceline, the three pharmacy wholesalers, and the Costco trials into incremental revenue.
• Deliver the targeted >$1 million annualised operating savings to support breakeven and cash generation.
• Execute a funding plan to simplify the debt stack, including addressing the $2.969 million in related party loans.

If Wellnex Life can string those together, the sharp reduction in loss this half could be the prelude to sustainable profitability.

Note: All figures are as disclosed by Wellnex Life Limited for the half-year ended 31 December 2025. Currency is Australian dollars.